Anti-UNC5c antibodies and uses thereof
Antibodies targeting UNC5C's discontinuous epitope, developed from human antibody libraries, offer a solution for neurodegenerative diseases by enhancing UNC5C binding, addressing the lack of effective therapeutic options.
AU2024398768A1Pending Publication Date: 2026-07-09ALCHEMAB THERAPEUTICS LTD
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- ALCHEMAB THERAPEUTICS LTD
- Filing Date
- 2024-12-13
- Publication Date
- 2026-07-09
Smart Images
Figure 00000000_0000_ABST
Abstract
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and / or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Need to check novelty before this filing date? Find Prior Art